Overview of the 1st and 2nd Generation EGFR-Targeting Tyrosine Kinase Inhibitors (TKIs)
Bonanno L, et al. Br J Cancer. 2022;127(3):383-393.
TATTON: a multi-arm, phase 1b trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR, et al. Ann Oncol. 2020;31(4):507-516.
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase 1 study.
Park K, et al. J Clin Oncol. 2021;39(30):3391-3402.
Ramalingam SS, et al; FLAURA Investigators. N Engl J Med. 2020;382(1):41-50.
A randomized phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, et al; ETOP 10-16 BOOSTER Collaborators. Ann Oncol. 2022;33(2):181-192.
Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
Wang H, et al. BMC Cancer. 2023;23(1):289.
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
Zhang L, et al. Thorac Cancer. 2023;14(15):1355-1361.
Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial.
Zhou C, et al. JAMA Oncol. 2021;7(12):e214761.